Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17371044 | 0.92 | CA1 (0.40) | CA1CA2CA9LMNAPDE4A | |
| SCHEMBL33146 | 0.80 | PDE4A (0.48) | CA1CA2CA9LMNAPDE4A | |
| SCHEMBL17371046 | 0.80 | CA1 (0.44) | CA1CA2CA9LMNAPDE4A | |
| SCHEMBL8166873 | 0.80 | LMNA (0.61) | LMNAPDE4ACYP1A2CYP2C19GAA | |
| SCHEMBL14869406 | 0.80 | LMNA (0.61) | LMNAPDE4ACYP1A2CYP2C19GAA | |
| SCHEMBL21325722 | 0.79 | CA1 (0.35) | CA1CA2CA9LMNAGAA | |
| SCHEMBL13765582 | 0.78 | IDH1 (0.53) | LMNAGAAL3MBTL1TDP1BCHE | |
| SCHEMBL19670086 | 0.78 | CA1 (0.39) | CA1CA2CA9LMNAPDE4A | |
| SCHEMBL13752164 | 0.78 | CA1 (0.43) | CA1CA2CA9CYP1A2CYP2C19 | |
| SCHEMBL27871771 | 0.77 | PDE4A (0.46) | CA1CA2CA9LMNAPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399611-B2 | Method of acetalizing an aldehyde | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-07-26 | — | — | US | disclosed |
| US-9399611-B2 | Method of acetalizing an aldehyde | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-07-26 | — | — | US | disclosed |
| US-20150080612-A1 | METHOD OF ACETALIZING AN ALDEHYDE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-19 | — | — | US | disclosed |
| US-20150080612-A1 | METHOD OF ACETALIZING AN ALDEHYDE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080612-A1 | METHOD OF ACETALIZING AN ALDEHYDE | ALDOA, ADH1A, ALDH2 | CA1 401/4885CA2 1892/4885CA9 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.